Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Lonza has introduced an enhanced product line aimed at tackling concerns around bias during blinded clinical trials.
read more
Lonza, a CDMO partner to the biopharma industry, announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies, under a long-term agreement. At scale, and following ...
read more
Lonza announced an endothelial cell application center, which expands Lonza’s support for researchers.
read more
Thursday, February 18, 2021
Lonza announced an expansion of its solid form selection services based at its Bend, OR (USA) site.
read more
Lonza has announced additional investments in its global particle engineering network for expanded capacity and specialized capabilities.
read more
Tuesday, October 27, 2020
Lonza announced a $93m investment in its CHI Division, a dosage form delivery partner to the biopharma and health nutrition industry.
read more
Tuesday, October 09, 2018
Lonza announced an expansion of its highly potent API capacity for the specific support of antibody drug conjugate payload manufacturing.
read more
Lonza announced an expansion of its highly potent API (HPAPI) capacity for the specific support of antibody drug conjugate (ADC) payload manufacturing.
read more
Wednesday, December 02, 2020
Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa, Florida site.
read more
Thursday, December 10, 2020
Lonza has announced an investment to expand its particle engineering and drug product capabilities at its Oregon site.
read more
Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third ADC produced at the site.
read more
Lonza announced the completion of a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China. The expansion focused on extending the capabilities and capacity of development laboratories and kilogram-...
read more
Tuesday, February 21, 2017
Lonza now offers cryopreserved lung fibroblasts isolated from donors diagnosed with Idiopathic Pulmonary Fibrosis (IPF) for use in research into this potentially fatal condition.
read more
Wednesday, March 27, 2019
Lonza has introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs.
read more
Lonza announced the establishment of a Center of Excellence for Dry Powder Inhaler drug product development at its OR site.
read more